Ustekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results Save

615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks. At 100 weeks, all groups significantly improved dactylitis and enthesitis scores, ACR20 (56.7-63.6%), DAS28-CRP moderate/good response (71.9-76.7%), and PASI75 (63.9%-72.5%) scores. Radiographic benefits were preserved through 100 weeks and the rate and type of AEs were similar between the dose groups.